Diazepam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Diazepam

Examples of brand names: Valium [DE]

ATC code: N05BA01

Main use (for orientation): Anxiety; seizures; muscle spasms

Documented research summary

Controlled human findings exist for THC; for CBD there is a non-randomised nasal-spray analysis and preclinical data. Results are not interchangeable or general approval of the combination.

Uncertainties and limitations

Post-hoc analysis without randomised CBD allocation; no pharmacokinetic measurement. Intermittent nasal administration is not chronic oral use; the theoretical CYP effect remains unquantified.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Direct pair finding

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Pair-specific evidence, distinguished in the individual findings

Mechanism / drug context: GABAergic depression; diazepam metabolism via CYP2C19/3A; assess exposures separately.

Type of supporting material: See the separate original findings

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral diazepam as Valium; active, with active metabolites; not a prodrug. Nasal-spray study considered separately.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0065]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: VALIUM (DIAZEPAM) TABLET [WAYLIS THERAPEUTICS LLC] [CA_L_D0065]

Source role [CA_P_25124305]: Pair finding

Statement supported: Diazepam caused sedation; some combinations increased heart rate and impaired task performance.

Source: Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC. [CA_P_25124305]

Source role [CA_P_37210793]: Pair finding

Statement supported: No clear additional safety signal attributed to diazepam nasal spray.

Source: Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. [CA_P_37210793]

Source role [C_PR_41050418]: Pair finding

Statement supported: The combination reduced mortality and the resistant seizure phenotype in a rat model.

Source: Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model. [C_PR_41050418]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: Complete saved individual review, label assessment, literature screening, conclusion and uncertainties read. Original information selectively rechecked by section; no complete revalidation of all prescribing information or full texts claimed. CBD/nasal-spray and rat study assessed using saved original abstracts; current full-text retrieval unsuccessful.

Separately recorded findings

3 separately recorded findings. Each statement applies to its documented study context.

Δ9-THC – clinically investigated

Finding ID: V6_D0065_1

Type of result: Finding within the documented study context

Observation: Diazepam caused sedation; some combinations increased heart rate and impaired task performance.

Mechanism: Pharmacodynamic/autonomic effects

Study type: Controlled human laboratory study

Context studied: Ten cannabis users, oral exposure; Lile et al. 2014.

Clinical interpretation: Functional impairment possible.

Limitations and uncertainties: Small selected population; not a general pharmacokinetic/safety assessment.

Original sources for this finding: Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC. [CA_P_25124305]

CBD – clinical signals

Finding ID: V6_D0065_2

Type of result: No clear additional signal under the conditions studied

Observation: No clear additional safety signal attributed to diazepam nasal spray.

Mechanism: Safety observation, not direct pharmacokinetic measurement

Study type: Post-hoc analysis of an open-label long-term study

Context studied: 163 people; 23 purified CBD, 21 other CBD forms, 119 without CBD.

Clinical interpretation: No general assurance of safety.

Limitations and uncertainties: CBD groups differed in illness and had more events overall; not randomised, not transferable to continuous oral therapy.

Original sources for this finding: Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. [CA_P_37210793]

CBD – laboratory and animal studies

Finding ID: V6_D0065_3

Type of result: Finding within the documented study context

Observation: The combination reduced mortality and the resistant seizure phenotype in a rat model.

Mechanism: Pharmacodynamics in induced seizures

Study type: Animal experiment

Context studied: Male Wistar rats; repeated 3-mercaptopropionic acid exposure.

Clinical interpretation: No clinical conclusion.

Limitations and uncertainties: Model-specific, not a dosage recommendation.

Original sources for this finding: Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model. [C_PR_41050418]

References and access status

[CA_L_D0065] VALIUM (DIAZEPAM) TABLET [WAYLIS THERAPEUTICS LLC]

Original source / bibliographic reference

Authors: Waylis Therapeutics LLC

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_25124305] Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.

Original source / bibliographic reference

Authors: Lile JA, Kelly TH, Hays LR.

Year: 2014

Source type: Controlled Clinical Trial; research-article; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1016/j.drugalcdep.2014.07.016

PMID: 25124305

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_37210793] Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study.

Original source / bibliographic reference

Authors: Peters JM, Puri V, Segal E, Misra SN, Rabinowicz AL, Carrazana E.

Year: 2023

Source type: Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.yebeh.2023.109248

PMID: 37210793

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_41050418] Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model.

Original source / bibliographic reference

Authors: Fuentes-Mejia M, Fallico MJ, Talevi A, Gavernet L, Orozco-Suárez SA, Rocha L.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3389/fphar.2025.1644018

PMID: 41050418

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility